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Background: Over the years, the treatment of oropharyngeal cancer has changed; in the past, first-line treatment
consisted of surgery followed by adjuvant radiotherapy, today however, primary treatment typically involves concomitant
chemoradiation, and reserves surgery for salvage. While chemoradiation is the modality of choice for primary
management of oropharyngeal cancer, disease characteristics, institutional bias, and patient preferences influence
treatment choice. This has lead to variation in the treatment of OPC, and has generated some uncertainly regarding the
ideal therapeutic approach. The objective of this study was to describe the treatment of OPC a large Canadian referral
center, highlighting trends in treatment choice and outcome.
Methods: This is a cross-sectional retrospective review of clinical practice at Sunnybrook Health Science Centre
(Toronto, ON). This investigation documents type of first-line treatment, rates of treatment failure, rates of surgical salvage,
and 5-year disease-free survival. This study also asses the therapeutic impact of free-flap reconstruction on the use of a
postoperative tracheostomy and/or percutaneous endoscopic gastrostomy tube.
Results: The majority of oropharyngeal cancer patients presented with regionally metastatic disease (stage III-IV)
and underwent concomitant chemoradiation as first-line treatment. Just over half of patients who failed
chemoradiation were eligible for salvage surgery. Forty-six percent of salvage patients recurred at approximately
6 months, and died approximately 12 months following the first sign of disease recurrence. Five-year survival for
salvage patients stage II, III, IVA, and IVB was 100%, 54.5%, 53.8%, and 50%, respectively. The incidence of
percutaneous endoscopic gastrostomy tubes and tracheostomies was comparable between patients who
underwent free-flap reconstruction and patients who did not.
Conclusion: The modality of choice for first-line treatment of oropharyngeal cancer is concomitant
chemoradiation. The moderate failure rate following chemoradiation and the modest survival rate following
salvage surgery could indicate that selected patients may benefit from undergoing surgery as first-line treatment.
While this study did not show that functional outcomes were better for free-flap patients, it is highly likely that
those who received a free-flap did better then they would have had they not undergone reconstructive surgery.
More research regarding the therapeutic effects of free-flaps in OPC survivors is needed.
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Oropharyngeal cancer (OPC) currently ranks 13th among
the most common forms of cancer in Canada, and ac-
counts for 475 newly diagnosed cases of cancer each year.
a Documented risks for OPC include male sex, alcohol and
tobacco use, and HPV infection [1-3]. While OPC is more
common in individuals 60 years of age or older, the rise in
HPV-related cancers has lead to an increase in disease inci-
dence in younger populations [3].
In the past, the treatment of OPC has involved surgery
followed by adjuvant radiotherapy (RT). Today, most
treatment regimes favor concomitant chemoradiation
(CCRT), reserving surgery for salvage. While CCRT is
now considered the standard in OPC treatment, disease
characteristics, patient preferences, and institutional
biases have substantial bearing on treatment decisions.
This has lead to institutional differences in first-line
treatment of OPC and has generated some uncertainty
regarding the ideal therapeutic approach [1].
The principle aim of this study is to describe the treat-
ment of OPC at a tertiary Canadian institution, and add to
the Canadian literature on the management and outcomes
of OPC. This research describes first-line treatment, the




Patients were identified using the Head and Neck Data-
base maintained by the Department of Otolaryngology–
Head and Neck Surgery, at Sunnybrook Heath Science
Centre (SHSC). The Head and Neck Database contains a
subset of patients treated for head and neck cancer at
SHSC from January 2004 to January 2013. All patients
who presented in the Cancer Center at SHSC with oro-
pharyngeal primaries and squamous cell carcinoma were
eligible for inclusion. Patients were excluded if they pre-
sented with a second primary that did not involve the
oropharynx or if they had initiated cancer treatment
prior to their presentation at Sunnybrook. Patient char-
acteristics are provided in the results section of this
paper.
Data collection
All patient data was handled according to standards set
forth by the Sunnybrook Research Ethics Board. Elec-
tronic patient records, available through the Sunnybrook
network, were used to collect patient data. Variables in-
cluded age at the time of diagnosis, sex, drinking and
smoking histories, site of involvement, TNM stage, dis-
ease stage, first-line treatment, response to primary
treatment, disease outcomes following primary treat-
ment (i.e. disease-free survival and overall survival) time
to recurrence following primary treatment, secondarytreatment (i.e. salvage surgery), salvage procedures, dis-
ease outcomes following salvage surgery (i.e. disease-free
survival and overall survival), time to recurrence follow-
ing salvage surgery, use of a post-salvage percutaneous
endoscopic gastrostomy tube (PEG-tube) and/or trache-
ostomy. All patients were staged using the 6th edition of
the American Joint Committee on Cancer (AJCC) 2010
staging system for oropharygeal cancer [4]. Time to re-
currence was measured from the completion of primary
treatment to the first sign of disease recurrence (clinic-
ally or radiologically). Survival was measured from the
completion of treatment to the time of death, or
60 months of clinical follow-up. Patients that had clin-
ical reports that ended before the 60-month mark were
censored. The presence/absence of PEG-tubes and/or
tracheostomies was documented along four different
time points: (1) start of treatment, (2) 6 months follow-
ing the completion of treatment, (3) 12 months follow-
ing treatment, and (4) 60 months following treatment.
Response to treatment was defined as complete, incom-
plete, or partial. Patients were considered to have a
“complete” response if full locoregional control was
achieved. Patients who did not respond to treatment, ex-
perienced disease progression, or were unable to
complete their therapy due to toxicity/intolerable side
effects were considered “incomplete”. A patient who had
a “partial” response showed signs of improvement fol-
lowing treatment amounting to at least a 50% reduction
in tumor volume. Patients who had a complete response
and remained disease-free over 60 months of clinical
follow-up or more were considered cured. Patients who
had a partial response or experienced a recurrence and
were not eligible for secondary treatment with curative
intent were considered palliative. Patients amenable to
further treatment went on to have salvage surgery. All
patients were assigned a disease status at the end of their
treatment: no evidence of disease (NED), alive with dis-
ease (AWD), dead of disease (DOD). If a patient was re-
ferred to palliative care, they were considered DOD by
the start of the following year.
Due to the fact that HPV testing is currently not yet
part of standard practice for the diagnosis and treatment
of OPC, very few patient records had this information
available. Low reporting of HPV status made an analysis
impossible. Therefore this information was not included
in this study.
Analysis
Analyses were performed using IBM SPSS GradPack statis-
tics software, version 21. Results were deemed significant if
p < 0.05, and highly significant If p < 0.01. A chi-squared
test was used to compare sets of parametric data, and an
unpaired students t-test was used to compare the means of
independent samples. The survival analysis was conducted
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curves were analyzed using a Mantel-Cox log rank test.
Results
Patient characteristics
One hundred and seventy-seven newly diagnosed oro-
pharyngeal cancer patients were identified and 153 were
eligible for inclusion. Patients who were excluded did
not have an oropharyngeal primary and/or did not have
squamous cell histology, and/or were presenting for the
first time to SHSC with recurrent disease. Of all the
OPC patients included in this study, 41 (26.9%) were fe-
male, and 112 (73.0%) were male. The mean age for all
patients was 62.1 (±12.1) years, and ranged from 26 to
93. Twenty-five (16.3%) patients had no history of smok-
ing or drinking, and 129 (83.7%) had a history of smok-
ing and/or drinking; the majority of which (65%) had a
history of both smoking and drinking. There were no
patients with in situ, stage I, or stage IVC disease. The
majority (55.6%) of patients were stage IVA, followed by
stage III (27.0%), stage IVB (13.0%), and then stage II
(4.6%). b One hundred and twenty-five patients (81.7%)
had regional metastases at first presentation, the major-
ity of which occurred in level II (67.2%). Few patients
presented with nodal involvement in more than one
neck level (16.8%), and/or extracapsular extension
(1.6%). Most OPC patients (55.6%) had tonsil primaries,
followed by the base of tongue (38.6%), the posterior
pharyngeal wall (3.9%), and then the soft palate (2.0%).
The tonsil and base of tongue had a tendency to present
with more advanced stage disease compared to theFigure 1 Percentage of patients with OPC who presented with base o
primaries (n = 153).posterior pharyngeal wall and soft palate cancers. Ninety-
seven percent of base of tongue cancers were stage III or
higher, and 94% of tonsil cancers were stage III or higher. A
percent distribution of sub-site is provided in Figure 1. A
cross-tabulation of site of involvement and disease stage
can be found in Table 1.
First-line treatment of OPC and the incidence of
treatment failure
One hundred and thirty-nine patients (90.8% of patients
with OPC) were treated with curative intent at first visit,
and 14 (9.2%) were considered palliative. Of those who
were considered palliative, 10 were stage IVA and 4
were stage IVB. Nearly 80% of patients had T4b tumors,
and 85.7% presented with advanced neck disease. The
majority of patients also had with significant comorbid-
ity, and/or a low functional status rating. All but one of
the patients treated with palliative intent received RT, 3
of these patients died before the completion of their
last fraction and the remaining patients died within
24 months of their diagnosis.
Fifty patients (36% of patients treated with curative in-
tent) received RT as their primary mode of care. The aver-
age dose of RT was 62 Gy (R = 32-70 Gy), delivered in 31
fractions, over 1 to 3 phases. Thirty-nine patients (78% of
patients treated with RT) had a complete response, 7 (14%)
had a partial response, and 4 were lost to follow-up. Of the
patients who had a complete response, 18 (46.2%) were
cured of their disease, 14 (35.9%) developed recurrent
tumors, and 4 (10.3%) developed second primaries. The
average time to recurrence following RT was 13.0 (±11.4)f tongue, posterior pharyngeal wall, soft palate, and tonsil
Table 1 Cross-tabulation of site of involvement and
disease stage for oropharyngeal cancer patients treated
at Sunnybrook Health Science Centre
Site of involvement Disease stage
II III IVA IVB
Base of tongue 2 17 31 9
Posterior pharyngeal wall 0 3 3 0
Soft palate 1 2 0 0
Tonsil 4 19 51 11
Cross-tabulation of site of involvement and disease stage for OPC (n = 153).
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treatment failure following RT were considered operable
and proceeded with salvage surgery (5 recurrent tumors,
3 second primaries, and 3 residual tumors). Figure 2 pro-
vides a complete overview of patient treatment and clinical
response.
Eighty-eight patients (64% of patients treated with cura-
tive intent) received CCRT as their primary mode of care.
The average dose of CCRT was 66 Gy (R = 50-70 Gy), de-
livered in 33 fractions, over 1 to 3 phases. There was only 1
patient that received adjuvant CCRT following surgical re-
section. Sixty-three patients (71.6% of patients treated with
CCRT) had a complete response, and 26 (29.5%) had a par-
tial response. Of those who had a complete response, 51
patients (81%) were cured of their disease, 9 (14.2%)
experienced a recurrence, and 3 (4.8%) developed second
primaries. The average time to recurrence was 23.7 (±20.1)
months and ranged from 3 to 60. Seventeen patients withFigure 2 Path model for cohort of OPC patients detailing prognosis a
treatment (branch 3), and salvage rate (branch 4) (n = 153).treatment failure following CCRT were deemed eligible for
salvage surgery [2 recurrent tumors, and 15 residual tumors
(Figure 2)]. The Sunnybrook experience of surgical salvage
will be discussed in the next section.
A chi-squared test was performed to determine whether
treatment failure was significantly different for patients who
received CCRT as opposed to RT. Results indicate that re-
currence rates and the incidence of second primaries were
higher for the RT group (35.9% vs. 14.3%; p < 0.001), and
the incidence of residual disease was higher for the CCRT
group (29.5% vs. 14.0%; p < 0.001). Time to recurrence was
comparable between the two groups (p >0.05). A subse-
quent chi-squared test was performed to determine
whether disease characteristics were homogenous between
the two treatment groups. Patient characteristics including
T-stage and site of involvement were not significantly dif-
ferent for patients who underwent RTas opposed to CCRT.
N-stage (p < 0.001) and disease stage (p < 0.001) were sig-
nificantly different between the two treatment groups. Ac-
cordingly, there were more patients with an N-stage <1 and
a disease-stage < III in the RT group, and were more pa-
tients with an N-stage > 2 and a disease stage > IVA in the
CCRTgroup. A student’s t-test was performed to determine
whether the age of patients was significantly different for ei-
ther of the treatment groups. The mean age of patients
undergoing CCRT and RT was 57.7(±10.1) and 67 (±11.3),
respectively; this difference was highly statistically signifi-
cant [t = 9.3 (95%CI: 13.1–5.7), p < 0.001]. Patient survival
for the RT and CCRT groups was 65.2% and 54.9%. Differ-
ences in survival were not significant.t first visit (branch 1), first-line treatment (branch 2), response to
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ally younger and presented with more advanced disease
stage, and specifically more advanced neck disease, com-
pared to patients who received RT alone. See Table 2 for
a breakdown of patient characteristic for each of the
treatment groups including site of involvement, disease
stage, N-stage, and T-stage.
Salvage surgery
Sixty-three patients treated with curative intent experienced
treatment failure: 33 (52.4%) were residual tumors, 23
(36.5%) were recurrent tumors, and 7 (11.1%) were second
primaries (Figure 3). Of the 28 patients who presented with
recurrent tumors or a second primary, the average time to
treatment failure was 16.7 (±15.9) months and ranged from
3 to 60. Thirty-five patients with treatment failure were
considered inoperable. Patients were considered inoperable
if they presented with advanced disease involving extensive
tumor spread and specifically if the tumor involved vital
structures (i.e. the major vessels) or distant sites. Further-
more, most of these patients were 60 years of age or older
and elected to forgo salvage surgery because they felt that
the likelihood of a cure did not outweigh the risk of surgical
morbidity. Twenty-eight patients (44.4% of patients who
experienced treatment failure) went on to have salvageTable 2 Patient characteristics for RT and CCRT cohorts
Site of involvement RT group CCRT group
Base of tongue 21 33
Posterior pharyngeal wall 2 1
Soft palate 2 1
Tonsil 25 55

















Comparison of site of involvement, T-stage, N-stage, and disease stage of
patients who underwent RT (n = 50) as first-line treatment as opposed to CCRT
(n = 88); **Significant to 0.01.surgery. Twenty patients underwent a neck dissection in
addition to local tumor excision, 7 patients underwent local
tumor excision alone, and 1 patient had a neck dissection
alone. c Five-year survival for salvage patients stratified by
primary disease stage II-IVB was 100%, 54.5%, 53.8%, and
50%; differences in survival were not statistically significant
(p > 0.05). Refer to Figure 4 for 5-year survival of salvage
patients. Fifteen (53.6%) patients who underwent surgical
salvage were cured of their disease. Of those who recurred
following surgical salvage: 4 developed distant tumors, 5
had a locoregional recurrence, 3 developed second primar-
ies, and 1 developed a third primary. The average number
of months to failure following salvage was 6.7 (±3.3) and
ranged from 2 to 11. Overall survival for these patients was
13.1 (±7.1) months and ranged from 3 to 28.
Free-flap reconstruction
Of the 28 patients that underwent salvage surgery, 15
(53.6%) underwent free-flap reconstruction. All patients
that underwent free-flap reconstruction had undergone
primary tumor excision with a neck dissection. The ra-
dial forearm was the most common donor site; other
free flaps included anterolateral thigh, and subscapular
system flaps. There were no intra-operative or postoper-
ative complications associated with free-flap reconstruc-
tion, and none of the 15 flaps failed postoperatively. Of
the patients that did not undergo free-flap reconstruc-
tion, 4 underwent primary tumor excision, 8 underwent
primary tumor excision and neck dissection, and 1
underwent a neck dissection alone.
Comparison of free-flap and non-free-flap patients
regarding use of post-salvage PEG-tubes and/or
tracheostomies
At 0, 6, 12 and 60 months following salvage surgery 11
(73.3%), 8 (53.3%), 6 (40%), and 3 (20%) free-flap patients
had a PEG-tube; and 5 (38.4%), 4 (30.8%), 3 (23.1%), and 2
(15.4%) non-free-flap patients had a PEG-tube. At 0, 6, 12
and 60 months following salvage surgery 4 (30.1%), 4
(30.1%), 3 (23.1%), and 0 free-flap patients had a tracheos-
tomy; and 3 (23.1%), 2 (15.4%%), 2 (15.4%), and 1 (7.8%)
non-free-flap patients had a tracheostomy. Tracheostomy
and PEG-tube status of patients with and without a free
flap is depicted in Figure 5. Relative risk (RR) with a 95%
confidence interval was used to determine whether the
need for a PEG-tube or tracheostomy was different between
patients who underwent free-flap reconstruction compared
to those who did not. Patients who underwent free-flap re-
constructions were consistently more likely to require a
PEG-tube at 0, 6, 12, and 60 months of clinical follow-up,
however, these results did not reach statistical significance
(p > 0.05). Similar results were obtained for use of tracheos-
tomy, though the risk was reversed at 60 months of clinical
follow-up; RR was not statistically significant (p > 0.05).
Figure 3 Summary of clinical response to primary treatment including type of treatment failure, surgical salvage, and disease
outcomes following salvage surgery (pooled data from Figure 2).
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The sample of OPC patients included in this study was
predominantly composed of males, aged 60 year or
older, with a history of smoking and/or drinking. The
majority of patients who presented with oropharyngealFigure 4 Kaplan Meier curve showing 5-year survival of OPC patients
green: III, yellow: IVA, purple: IVB.primaries were treated with curative intent. Only a small
number of patients were considered incurable, and this
was due to the advanced nature of their disease. Surgery
as first-line treatment was rare and was only performed
in one patient. d This finding aligns with current trendsfollowing surgical salvage; p value not significant: blue: stage II,
PEG-tube status for PEG-tube status for 
Free-flap patients non-free-flap patients
Tracheostomy status for Tracheostomy status for 
















































































Figure 5 Top two graphs: number of patients with (blue) and without (green) a PEG-tube at 0, 6, 12, and 60 months post-operative
following salvage surgery. On the left are patients who underwent free-flap reconstruction, and on the right are patients who did not undergo
non-free-flap reconstruction. Bottom two graphs: number of patients with (yellow) and without (red) a tracheostomy at 0, 6, 12, and 60 months
post-operative following salvage surgery. On the left are patients who underwent free-flap reconstruction, and on the right are patients who did
not undergo non-free-flap reconstruction.
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over surgery as first-line approach [1,5]. In this study,
CCRT was administered more frequently than RT. This
result reflects the fact that the majority of OPC patients
presented with regional involvement (N ≥ 2), and chemo-
therapy is thought to be the best modality for themanagement of OPC with neck disease. This analysis re-
vealed that the rate of residual disease was higher for pa-
tients who underwent CCRT compared to those who
underwent RT. Because patients who received CCRT
typically presented with more advanced disease than
those treated with RT, the higher incidence of residual
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treatment modality. In contrast, despite the fact that re-
gional metastasis is associated with a higher risk of re-
currence, and patients in the CCRT group generally
presented with more advanced neck disease, the rate of
recurrence was significantly lower for the CCRT group
compared to the RT group. This finding supports the
notion that chemotherapy is superior to RT for the man-
agement of nodal metastasis. This investigation did not
find a significant difference in the length of disease-free
survival between the two treatment groups; however, the
lack of significant findings may have been attributed to
the degree of variability in the time to recurrence within
each group.
Of all patients who experienced treatment failure, just
over half were amenable to surgery. There are a number
of variables that factored into the decision to proceed
with salvage surgery. In order for patients to be eligible
for salvage surgery, tumors must be minimally invasive
and cannot involve vital structures (i.e. major vessels)
and/or multiple/distant sites, and patients must present
with minimal comorbidity and a moderate to high func-
tional status rating. While the majority of salvage pa-
tients were cured of their disease following salvage
procedures, the failure rate was relatively high at 39%.
According to Cohen et al., it is still unclear whether
CCRT followed by salvage surgery is really more effective
than surgery followed by adjuvant CCRT [1]. Proponents of
the organ-sparing approach argue that administering CCRT
as first-line treatment offers patients a chance of a cure
while sparing them from the risk of surgical morbidity.
However, if close to half of patients fail following CCRT
then many patients still end up requiring surgery. The issue
is that by the time patients fail following CCRT only about
half are eligible for further treatment, and out of those who
undergo surgical salvage, only about half will be cured of
their disease.
Since the introduction of free flaps in the late 80’s,
postoperative functional rehabilitation has significantly
improved [6]. According to Stoker et al. combined-
modality treatment of OPC that includes free-flap recon-
struction enhances post-salvage outcomes by improving
airway management. In this study, the risk of PEG-tubes
and tracheostomy was comparable for those who under-
went free-flap construction compared to those who did
not. Though this finding seems to contradict previous
findings demonstrating that free-flap reconstruction is
associated with improved functional rehabilitation. Our
results may have been a consequence of the small sam-
ple size or due to the fact that most of the patients
undergoing free-flap reconstruction were subjective to
more invasive procedures. It is worth pointing out that
despite the fact that the instance of PEG-tube use was
higher among free-flap patients, there were more free-flap patients who had their PEG-tube removed over the
course of 60 months. Because this study did not include
a valid comparator for free-flap patients, the therapeutic
advantage of free-flap reconstruction could not be dir-
ectly quantified; however, it is very possible that those
who received a free flap were rid of their PEG-tube and/
or tracheostomy sooner than they would have if they
had not received a free-flap.
Conclusion
While the modality of choice for first-line treatment of
OPC is CCRT, moderate failure rates suggest that se-
lected patients may be better off with surgery as first-
line treatment. While treatment-related morbidity is a
concern with surgery, it is important to point out that
not all surgeries are associated with a high risk of mor-
bidity. For instance, it may be the case that less invasive
procedures such as transoral laser surgery with inte-
grated neck dissection are better tolerated and could
therefore be regarded as a reasonable alternative to
CCRT. Continued research comparing the efficacy of
different therapeutic approaches involving a combin-
ation of surgery and CCRT is needed and on the thera-
peutic potential of free-flap reconstruction in patients
undergoing surgical salvage for recurrent or residual
OPC primaries is needed.
Endnotes
aYearly mortality rates specific to oropharyngeal cancer
(OPC) are currently unavailable.
bFive-year survival for disease stages II through IVB
was 71.4%, 64.3%, 57.0%, and 40%. Differences in sur-
vival proportions by disease stage were statistically sig-
nificant (p = 0.05).
cThere were 8 patients who underwent an salvage neck
dissection following CCRT, however, surgical pathology
did not come back showing residual disease, therefore
even though these patient underwent salvage surgery
they were not considered to have treatment failure and
were therefore excluded from the following analysis. The
vast majority of neck dissections were unilateral modi-
fied radical.
dThis patient presented with significant boney invasion
of the mandible and required an immediate manibu-
loectomy. Surgery was followed by adjuvant CCRt. This
patient had a complete response and was cured of their
disease.
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